Recent work using culture-independent methods suggests that the lungs of cystic fibrosis (CF) patients harbor a vast array of bacteria not conventionally implicated in CF lung disease. However, sampling lung secretions in living subjects requires that expectorated specimens or collection devices pass through the oropharynx. Thus, contamination could confound results. Here, we compared culture-independent analyses of throat and sputum specimens to samples directly obtained from the lungs at the time of transplantation. We found that CF lungs with advanced disease contained relatively homogenous populations of typical CF pathogens. In contrast, upper-airway specimens from the same subjects contained higher levels of microbial diversity and organisms not typically considered CF pathogens. Furthermore, sputum exhibited day-to-day variation in the abundance of nontypical organisms, even in the absence of clinical changes. These findings suggest that oropharyngeal contamination could limit the accuracy of DNA-based measurements on upperairway specimens. This work highlights the importance of sampling procedures for microbiome studies and suggests that methods that account for contamination are needed when DNA-based methods are used on clinical specimens. lung explants | lung infection | microbial ecology | human microbiome | 16S rRNA sequencing M ost patients with cystic fibrosis (CF) die from progressive lung damage caused by chronic airway infections (1) . For many years, clinicians have focused on a relatively limited number of bacterial species in CF, including Haemophilus influenzae, Pseudomonas aeruginosa, Staphylococcus aureus, Burkholderia cepacia complex, and a few others (2) . These organisms have been considered "typical" CF pathogens and have been linked to disease pathogenesis by airway culture results, clinical experience, and epidemiological data (1, 3) .
However, recent work using culture-independent identification methods suggests that CF airways may be infected by many more bacterial species than appreciated previously (4) (5) (6) (7) (8) (9) (10) (11) . For example, analysis of bronchoalveolar lavage (BAL) samples found that ∼25% of children harbor organisms not typically associated with CF (9) .
Studies using newer methods are even more striking. Hundreds to thousands of bacterial taxa per patient have been found in throat and sputum samples analyzed with DNA-based methods (5) (6) (7) . This work has raised the possibility that previously unrecognized species may be present in the lower airways and contribute to the devastating clinical manifestations of CF. Indeed, these findings have begun to influence clinical practice recommendations and fundamentally alter understanding of the disease (12) (13) (14) .
An important outstanding question, however, is whether DNAbased analyses of upper-airway specimens accurately represent the composition of lung microbiota. This issue is critical because sputum, throat, and BAL samples are prone to contamination because bacteria from the mouth, sinuses, or pharynx could mix with expectorated samples or contaminate bronchoscopes and collection swabs (15, 16) . In addition, DNA-based measurements may be more sensitive than culture (17, 18) and, unlike cultures performed by clinical laboratories, results are not filtered to disregard organisms that could be contaminants (19, 20) . Finally, DNA-based methods are primarily used to identify organisms not typically considered pathogens in CF (12, 21) . Many of these species are normal inhabitants of upper airways (22) .
The goals of this study were to answer three key questions. First, how do DNA-based measurements on upper-airway specimens compare with directly obtained lung samples? Addressing this question is vital to interpreting culture-independent measurements on upper-airway samples obtained at any stage of the disease. Second, what bacterial taxa are present in the lower airways of CF patients with established chronic infections? Identifying the resident bacteria is critical to understanding disease mechanisms. Third, are different bacterial species consistently found in different anatomic regions of the lung? Finding such differences might explain the regional variation in lungdisease severity characteristic of CF (23) .
To answer these questions, we devised a sterile dissection technique to isolate secretions from the lobar airways of CF lungs removed at the time of lung transplantation. We then measured the composition of the airway microbiota using 16S rRNA gene amplicon pyrosequencing and compared results to paired throat and sputum samples collected hours earlier.
Results
Lung Explant Sampling. We devised sampling methods to meet several objectives. We sought to collect endobronchial secretions rather than tissue sections, because CF lung disease is thought to be caused by intraluminal bacteria (24) . We focused on lobar bronchi, because these are likely to be less prone to contamination via aspiration than the main airways, and because they should contain distal secretions brought forward by mucociliary clearance. In addition, we sought to minimize cross-contamination between lung segments, so that regional differences in microbiota could be identified. To accomplish these goals, we dissected lung parenchyma away from the exterior aspect of the airways without cross-sectioning the lungs. When lobar airways were located, their exterior surfaces were flash-burned and entered using a sterile scalpel, and secretions were sterilely aspirated. Both right and left lungs from each subject were sampled at three to six sites from each lung.
16S Amplicon Pyrosequencing for Bacterial Identification. We amplified 16S rRNA genes in 124 samples (85 lung samples from 10 subjects; 8 throat and 31 sputum samples) using primers 28F and 519R, which spanned variable regions V1 to V3. Primers 104F and 530R (spanning V2 to V3) were also used on some samples, with similar results obtained (Fig. S1 ). Amplicons were sequenced using Roche 454 FLX titanium technology. Throatswab samples generally yielded fewer reads (see below), likely because this method collects fewer bacteria. Random sampling was used to generate rarefied subsets of 8,000 reads from highyielding sputum and lung samples, so that comparable numbers of reads could be analyzed for the different sample types. Some samples were also analyzed using the Ribosome Database Project (RDP) classifier through Quantitative Insights into Microbial Ecology (Qiime) (25, 26) , with similar results obtained (Fig. S2 ). Clinicians and researchers use upper-airway samples to represent the overall composition of lung bacteria. Thus, we initially summed the sequencing reads of all samples from the right and left lungs of each subject, so that the data from lung samples could be compared with the upper-airway specimens. This analysis produced three main findings.
First, in contrast to the diverse microbiota found in previous analyses of throat and sputum specimens (5-7), direct sampling revealed that all subjects' lungs were dominated by at most three bacterial taxa (Fig. 1) . P. aeruginosa was dominant in 8 of 10 of the subjects, and in 6 subjects, it comprised >99% of all lung reads. The lungs of two other subjects were dominated by B. cepacia complex and Achromobacter xylosoxidans at 76% and 92% relative abundance, respectively.
Second, the vast majority of bacteria identified were typical CF pathogens ( Fig. 1 and Dataset S1, Table S1 ). Culture-based analyses have linked CF infections to a limited number of species, including H. influenzae, S. aureus, P. aeruginosa, Stenotrophomonas maltophilia, B. cepacia complex, and A. xylosoxidans. Below, we call these organisms "typical" CF pathogens, and refer to bacteria not previously thought to cause disease in CF as "nontypical" organisms. In every lung, typical pathogens comprised >98% of identified reads. A single nontypical species never exceeded 0.2% relative abundance in any of the 10 lungs we studied (Dataset S1, Table S1 ).
Third, we found striking concordance between sputum culture results used for the clinical care of subjects and the sequencing data from lungs. All lung genera identified at greater than 0.2% relative abundance by sequencing were also detected by preoperative clinical sputum cultures (Dataset S1, Tables S1 and S2). The converse was also true: all pathogens identified in clinical sputum cultures were found in the lung by sequencing. Although cultures did reveal nontypical organisms, the clinical laboratory classified these as "contaminating oral flora" and did not identify them further.
Throat Samples Poorly Reflect Lung Microbiota. The discrepancy between the direct lung samples and previous work that used upper-airway specimens as surrogates (4, (6) (7) (8) 27 ) led us to hypothesize that DNA-based measurements on upper-airway and lung samples from the same subject would be discordant. To test this, we first studied throat specimens obtained immediately before surgery. The throat and lung samples differed in several ways.
Throat specimens showed markedly higher levels of microbial diversity than lung samples obtained just several hours later (Figs. 2A and 3A). Furthermore, the predominant species identified in the throat did not match that found in the lungs. For example, the throat specimen of subject 9 was dominated by Fusobacterium and Prevotella, and P. aeruginosa was detected at 0.2% relative abundance. In contrast, lung samples obtained several hours later contained P. aeruginosa at a relative abundance of 73%, and neither Fusobacterium nor Prevotella was detected ( Fig. 2A and Dataset S1, Table S3 ).
Notably, most throat samples produced fewer reads than lung samples, likely because throat swabs collect fewer bacteria. Previous work shows that diversity can be underestimated when fewer reads per sample are analyzed (28) . Thus, the discordance between throat and lung samples may be even more pronounced than the data suggest.
Finally, throat specimens showed a high abundance of nontypical organisms that were either not found or found at very low levels in the lungs of subjects (Figs. 2A and 3B and Dataset S1, Table S3 ). These results indicate that throat specimens poorly reflect the microbiota of the CF lungs we studied.
Sputum Samples Identify the Dominant Organism but Can Overestimate
Diversity. We also obtained sputum from six subjects before surgery. In contrast to throat specimens, the predominant organism identified in sputum was also the most abundant in the lungs of subjects ( Fig. 2B and Dataset S1, Table S4 ). Furthermore, four of seven sputum samples (sputum samples 6-2, 7, 8, and 10) showed low levels of nontypical organisms and, thus, generally mirrored the lung samples in terms of the identity and relative abundance of taxa.
However, the other three sputum samples (samples 2, 6-1, 9) contained an array of nontypical organisms that comprised ∼25% of the microbiota. These nontypical organisms were 100-to 1,000-fold more abundant in sputum samples compared with the lungs of subjects (Fig. 2B and Dataset S1, Table S4 ). The two sputum samples from subject 6 were notable. One correlated with the lung, whereas the other (obtained 3 d earlier) showed a much higher abundance of nontypical organisms.
We also studied five additional subjects with advanced CF who had not undergone lung transplantation. Consistent with the results from transplant subjects, throat specimens were dominated by a diverse array of nontypical organisms that showed little overlap with the sputum samples ( Fig. S3 and Dataset 1, Table S5 ). Also consistent, sputum samples showed substantial variation in the relative abundance of nontypical organisms (range, 0.2-24% of the population) and the degree of diversity present ( Fig. S3 and Dataset S1, Table S5 ). Table  S1 and Fig. S5 .
We compared the lung, sputum, and throat data from all of the above subjects using the Shannon-Weaver diversity index. Samples from lungs showed the lowest diversity, sputum was intermediate, and throat samples were the most diverse (Fig.  3A) . A plot of the abundance of nontypical organisms showed the same correlation. Furthermore, sputum samples with the highest diversity indices (Fig. 3A) also contained the highest levels of nontypical organisms (Fig. 3B ).
Antibiotic Treatment Does Not Likely Explain Differences Between
Upper-Airway and Lung Samples Collected on the Same Day. Broadspectrum antibiotics are administered immediately before and during transplant surgery. We considered the possibility that the discrepancy between upper-airway specimens collected before surgery and lung samples obtained after surgery could be caused by the selective reduction of nontypical organisms by antibiotic treatment.
However, because subjects had advanced disease, all were on antibiotics at the time of hospital admission. Thus, subjects were being treated when the upper-airway samples were collected, and when lungs were removed several hours later. In fact, subject 6, was on an identical antibiotic regime when the upper-airway specimens were obtained and during surgery. Subjects 7 and 10 were treated with regimes with a similar spectrum of coverage (Dataset S1, Table S6 ) when upper-airway specimens were obtained and during surgery.
Thus, for perioperative treatment to cause the discordance between upper-airway and lung samples, treatment would have to eliminate nontypical organisms from lungs but allow these bacteria to persist in throat and sputum samples. This scenario seems unlikely. The fact that DNA-based methods readily detect bacteria killed by antibiotics and other mechanisms (29, 30 ) also makes it unlikely that abundant species were missed because of antibiotic killing.
Bacterial Overgrowth Does Not Likely Explain Upper-Airway Lung Differences. Another potential explanation for the discordance between lung and upper-airway samples pertains to the time delay between lung removal and DNA preservation. Whereas DNA from throat and sputum samples was preserved immediately upon collection, lungs were sampled several hours after removal and storage at 4°C, so that an autopsy pathologist could assist with the sterile dissection.
To determine whether this delay could confound results, we aerobically stored sputum samples for 24 h at 4°C (lungs were stored for 6-14 h). The extent of diversity identified was not markedly altered by storage, and the relative abundance of nontypical organisms such as oral anaerobes actually increased somewhat ( Fig. S4 and Dataset S1, Table S7 ). Thus, bacterial overgrowth or rRNA gene degradation does not likely account for the low abundance of nontypical organisms (including anaerobes) detected in CF lungs.
Regional Variation of Microbiota Does Not Likely Explain UpperAirway Lung Differences. As shown above, the relative abundance of nontypical organisms in sputum varied between subjects, even though these organisms represented a small fraction of the total lung reads in all subjects (Figs. 2B and 3B ). This variation could be explained if secretions from certain lung segments contained a high abundance of nontypical organisms, and secretions from these regions sometimes dominated expectorated samples. We explored this in two ways. First, we examined the relative abundance of species in each lobe of all 10 lungs (6-12 samples per lung pair). Although three lungs did show some regional variation in relative abundance of typical CF pathogens, most lung lobes closely mirrored the summed data representing the overall lung microbiota (Fig. 4, Fig. S5 , and Dataset S1, Tables S8-S17). None of the lobar samples contained large numbers of nontypical organisms found in some sputum specimens (Fig. S6) .
Second, we reasoned that secretions from main-stem bronchi might reveal nontypical organisms if they existed in the lung, because secretions from many regions may be mixed in the main airways. However, in cases where surgical margins permitted sampling, the main-stem bronchi contained a similar relative abundance of species as the summed data from lung segments (Fig. 4 A and B and Fig. S5 ). Furthermore, main-stem bronchi did not contain the nontypical organisms seen in some upper-airway samples (Fig. S7) . Thus, the discordance between lung and upperairway results is not likely explained by large numbers of nontypical organisms in discrete lung regions. Furthermore, we did not find consistent differences in the relative abundance of typical pathogens that could explain CF lung disease heterogeneity.
Sputum Samples Show Day-to-Day Variation in the Absence of Clinical
Changes. Our findings that perioperative antibiotics, pathogen overgrowth, DNA degradation, or regional variation in microbiota may not account for the differing results from upper-airway and lung samples suggests that fluctuating levels of contamination with oropharyngeal bacteria may be responsible. This hypothesis predicts that DNA-based analysis of sputum from individual subjects would show day-to-day variability.
Sputum samples from subjects collected on successive days showed variation in the abundance of nontypical organisms, even though the clinical state or treatment regime of the subjects had not changed (Fig. 5 and Dataset S1, Table S18 ). For example, the abundance of nontypical organisms varied from 0.4% to 28% in subject 11 and from 36% to 86% in subject 13. In some cases, the daily variation was severe enough to change the identity of the predominant taxa. In subject 13, collection from one day identified Pseudomonas as the predominant taxa, whereas Prevotella sp.
(not abundant in any lung sample) dominated a day later.
Discussion DNA-based analyses suggesting that CF airways may contain hundreds of bacterial species have upended established views of this disease. These findings used throat and sputum specimens as surrogates for lung microbiota. However, the sensitivity of DNAbased methods, and the fact that the data are not filtered to remove possible contaminants (as is the convention for culture results), raises questions about how to interpret the findings. Furthermore, studies examining the accuracy of DNA-based measurements on upper-airway samples are lacking.
Our work using direct sampling of explanted lungs from subjects with advanced disease show that typical CF pathogens comprise ∼98% of the microbiota, and lungs are dominated by Most lungs resembled that from subject 1 (A) and showed minimal regional differences. Some lobar regions from the lungs of subjects 3 (B) and 9 (C) showed differences in the abundance of typical pathogens. See Fig. S5 for data from other subjects. Ling., lingula; Ling. 2 , lingula second sample; LLL, left lower lobe; LLL 2 , left lower lobe second sample; L main, left main-stem bronchus; LUL, left upper lobe; RLL, right lower lobe; RLL 2 , right lower lobe second sample; RLL 3 , right lower lobe third sample; R main, right main-stem bronchus; RML, right middle lobe; RML 2 , right middle lobe second sample; RUL, right upper lobe; Sum, aggregate of all lung samples from each subject.
§ Samples that produced less than 5,000 reads (see Dataset S1, Tables S8, S10 , and S16).
only one to three species. In contrast, throat and sputum samples obtained from the same patients immediately before surgery gave different results. The throat specimens were highly discordant with lung samples, because they contained a wide range of nontypical organisms not found in the lungs of subjects. Sputum samples identified the dominant lung pathogen. However, in ∼1/2 of the cases, sputum contained diverse mixtures of nontypical organisms (comprising ∼25% of microbiota) that were either not found or were at very low abundance in the lungs of subjects. Furthermore, sputum specimens showed day-to-day variation in the abundance of nontypical organisms in the absence of clinical changes. These findings suggest that oropharyngeal contamination may confound DNAbased measurements on upper-airway samples.
Although we are not aware of other work comparing DNAbased measurements of upper-airway and lung samples, previous work using direct sampling of CF lung microbiota is limited and conflicting. Our findings are broadly consistent with a study examining five CF lungs removed at the time of transplantation, which showed that typical pathogens dominated the lungs (31). However, another study examining one postmortem and one explanted CF lung found a high abundance of nontypical organisms and marked regional heterogeneity (32) . This study differed from ours in that it focused on tissue rather than endobronchial samples, one of the two subjects underwent 3 wk of mechanical ventilation before death, and lungs were crosssectioned for sampling. These differences may account for the conflicting results.
Although direct sampling reduces the likelihood of oropharyngeal contamination, this approach has limitations. We explored the possibility that technical factors, such as bacterial overgrowth, DNA degradation, perioperative antibiotics, or regional heterogeneity in lung microbiota accounted for the discordant findings between upper-airway and lung samples. However, control experiments, the fact that subjects were receiving broadspectrum antibiotics when both upper-airway and lung samples were obtained, and our finding that lobar and mainstem airways contained few nontypical organisms suggested that these factors were not responsible.
We recognize that different processing methods could produce different results. Some investigators favor "washing" expectorated sputum to attempt to remove contaminates (4). We decided against this approach for a number of reasons. Previous work shows that certain organisms can preferentially localize to the external surface of aggregates containing multiple bacterial species (33) . Such organisms could be undersampled if sputum is washed. Furthermore, nasal and pharyngeal epithelia produce mucus that could encase upper-airway bacteria. Thus, washing may not eliminate mucus-encased contaminants.
We also decided against using techniques that limit detection to bacteria that are transcriptionally active or have intact membranes. These approaches have the advantage of reducing the signal from bacteria that are present, but fail to grow in the lung. However, they would also impair detection of organisms inhibited by host defenses and antibiotics. Because immune responses and antibiotic use is intense in CF, we thought that excluding these organisms would be a disadvantage.
It is important to note that lung explants were obtained from patients with advanced-stage CF. Thus, the low microbial diversity and high abundance of typical pathogens may be attributable to factors such as extensive antibiotic treatment or the competitive activities of pathogens like P. aeruginosa. However, the low diversity present in advance disease is an advantage for investigating the effect of upper-airway contamination, which was the primary goal of our study. Contaminants can be more clearly indentified against the background of a homogenous microbiota.
The prospect of contamination suggests that interpreting DNA-based analyses of upper-airway specimens may be complicated. For example, a primary reason these methods are used on CF samples is to detect nontypical bacteria (like S. milleri group and Prevotella). Our findings that sputum and throat samples contained these taxa even when they were not found in the lungs of subjects raise questions about how to determine whether organisms reside in the upper or lower airway.
Contamination could also complicate efforts to correlate microbial diversity with disease phenotypes. For example, if typical pathogens within CF lungs increase in advanced disease or during exacerbations, this could give the appearance of diminishing microbial diversity because oropharyngeal contaminants would be diluted and constitute a lower fraction of reads in upper-airway specimens.
A critical question for future research is: How abundant are nontypical pathogens at earlier stages of CF lung disease? Although studying lungs removed at transplant cannot answer this question, our data indicate that upper-airway samples may be problematic surrogates for lung microbiota when DNA-based methods are used. All throat and many of the sputum samples we showed variation in the abundance of nontypical organisms; however, Pseudomonas dominated in each. Specimens from subject 13 (C) showed day to day variation that changed the identity of the dominant taxa. § Samples that produced less than 5,000 reads (see Dataset S1, Table S18 ).
examined contained large numbers of 16S rRNA gene sequences from nontypical organisms even though these were of low abundance in lungs. Oropharyngeal contamination may confound DNA-based analyses of upper-airway samples in younger patients as well. Thus, new methods that limit or account for contamination are needed to identify the microbiota present in lungs of CF patients at all stages of the disease.
Methods
Patient Enrollment. Lung and, when possible, sputum and throat samples were obtained from 10 CF subjects undergoing lung transplantation. Five nontransplant subjects with forced expiratory volume in 1 s (FEV1) <30% predicted also provided throat and sputum samples. Three nontransplant subjects provided multiple-day sputum samples while clinically stable. Samples were collected between November 2009 and March 2011 with approval from University of Washington's institutional review board, and all patients provided informed consent.
Airway Sampling. Lungs were stored at 4°C for 6-14 h before dissection. Lung parenchyma was dissected from the main bronchi and its divisions. When lobar branches were identified, the airway wall was sterilized by contact with a flamed spatula and then entered using a sterile scalpel. Airway segments were lavaged with a sterile syringe containing 1 mL of sterile saline, and samples were weighed. Throat swabs were vortexed in 1 mL of sterile normal saline. All samples were kept at −80°C for later DNA extraction.
DNA Extraction and Sequencing. One-hundred-microliter aliquots of sputum and lung secretions and 200-μL aliquots of throat swab samples were processed using the MO BIO PowerSoil DNA isolation kit following the instructions of the manufacturer. DNA (100 ng) was used for 30 cycles of PCR with primers 28F (5′ GAG TTT GAT CNT GGC TCA G) and 519R (5′ GTN TTA CNG CGG CKG CTG) using the HotStarTaq Plus Master Mix Kit (Qiagen). Fifty-microliter reactions were run at 95°C for 5 min, followed by 30 cycles of 95°C for 30 s, 54°C for 40 s, and 72°C for 1 min. The final elongation step was at 72°C for 10 min. The 16S rRNA amplicons were sequenced using bacterial tag-encoded FLX-titanium amplicon pyrosequencing as described in SI Methods and refs. 34-36.
Bacterial Identification and Diversity Analysis. Quality trimming eliminated sequences (15% of the total) with ambiguous base calls, homopolymers > 6, quality scores < Q25, read lengths < 300 bp, and low-quality sequence ends and those without 100% match to barcodes. Random sampling was used to generate rarefied subsets of 8,000 sequences for samples that yielded more than 8,000 reads. Tags were removed, chimeras were depleted with Black Box Chimera Check (37) , and sequences analyzed as described in SI Methods and refs. 34, 38-40. Reads with identity scores > 97% to well-characterized 16S sequences were resolved to the species level, reads scoring between 95% and 97% were resolved to the genus level, reads scoring between 90% and 95% were resolved at the family level, and reads scoring between 80% and 90% were resolved to the order level. Tests of the sequence analysis methods are described in SI Methods. Ten throat and sputum samples were also evaluated using the Qiime pipeline (25) .
